Epidemiological and clinical aspects of immunoglobulin A vasculitis in childhood: a retrospective cohort study.
Abdominal Pain
/ epidemiology
Adolescent
Age Distribution
Anemia
/ epidemiology
Arthralgia
/ epidemiology
Arthritis
/ epidemiology
Blood Sedimentation
C-Reactive Protein
/ analysis
Child
Child, Preschool
Cohort Studies
Female
Glucocorticoids
/ therapeutic use
Hospitalization
Humans
IgA Vasculitis
/ epidemiology
Immunosuppressive Agents
/ therapeutic use
Infant
Infant, Newborn
Infections
/ epidemiology
Italy
/ epidemiology
Kidney Diseases
/ epidemiology
Leukocytosis
/ epidemiology
Male
Purpura
/ epidemiology
Retrospective Studies
Seasons
Sex Distribution
Thrombocytosis
/ epidemiology
Henoch-Schӧnlein purpura
Immunoglobulin A vasculitis
Pediatrics
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
15 Dec 2021
15 Dec 2021
Historique:
received:
19
07
2021
accepted:
09
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
19
1
2022
Statut:
epublish
Résumé
A retrospective study was conducted in order to investigate and describe the characteristics of Immunoglobulin A vasculitis (IgAV), previously known as Henoch-Schӧnlein purpura, in the paediatric population of a community-based healthcare delivery system in the Italian region of Abruzzo. This is a population-based retrospective chart review of the diagnosis of IgAV in children ages 0 to 18, admitted to the Department of Paediatrics of Chieti and Pescara between 1 January 2000 and 31 December 2016. All children enrolled presented with clinical symptoms and laboratory findings and met the EULAR/PRINTO/PRES 2008 criteria. Two-hundred-eight children met the criteria for IgAV, with the highest incidence reported among children below 7-years of age. A correlation with recent infections was found in 64% of the cohort; the onset was more frequently during the winter and fall. Purpura had a diffuse distribution in the majority of patients; joint impairment was the second most frequent symptom (43%), whereas the gastrointestinal tract was involved in 28% of patients. Hereby, we confirm the relative benignity of IgAV in a cohort of Italian children; with regards to renal involvement, we report a better outcome compared to other studies. However, despite the low rate of renal disease, we observed a wide use of corticosteroids, especially for the treatment of persistent purpura.
Sections du résumé
BACKGROUND
BACKGROUND
A retrospective study was conducted in order to investigate and describe the characteristics of Immunoglobulin A vasculitis (IgAV), previously known as Henoch-Schӧnlein purpura, in the paediatric population of a community-based healthcare delivery system in the Italian region of Abruzzo.
METHODS
METHODS
This is a population-based retrospective chart review of the diagnosis of IgAV in children ages 0 to 18, admitted to the Department of Paediatrics of Chieti and Pescara between 1 January 2000 and 31 December 2016. All children enrolled presented with clinical symptoms and laboratory findings and met the EULAR/PRINTO/PRES 2008 criteria.
RESULTS
RESULTS
Two-hundred-eight children met the criteria for IgAV, with the highest incidence reported among children below 7-years of age. A correlation with recent infections was found in 64% of the cohort; the onset was more frequently during the winter and fall. Purpura had a diffuse distribution in the majority of patients; joint impairment was the second most frequent symptom (43%), whereas the gastrointestinal tract was involved in 28% of patients.
CONCLUSIONS
CONCLUSIONS
Hereby, we confirm the relative benignity of IgAV in a cohort of Italian children; with regards to renal involvement, we report a better outcome compared to other studies. However, despite the low rate of renal disease, we observed a wide use of corticosteroids, especially for the treatment of persistent purpura.
Identifiants
pubmed: 34911536
doi: 10.1186/s13052-021-01182-6
pii: 10.1186/s13052-021-01182-6
pmc: PMC8672591
doi:
Substances chimiques
Glucocorticoids
0
Immunosuppressive Agents
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
237Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Oni L, Sampath S. Childhood IgA Vasculitis (Henoch Schonlein Purpura)-Advances and Knowledge Gaps. Front Pediatr. 2019;27(7):257.
doi: 10.3389/fped.2019.00257
Leung AKC, Barankin B, Leong KF. Henoch-schönlein purpura in children: an updated review. Curr Pediatr Rev. 2020;16(4):265–76.
doi: 10.2174/1573396316666200508104708
Lava SAG, Milani GP, Fossali EF, et al. Cutaneous manifestations of small-vessel leukocytoclastic vasculitides in childhood. Clin Rev Allergy Immunol. 2017;53(3):439–51.
doi: 10.1007/s12016-017-8626-3
Paller AS, Kelly K, Sethi R. Pulmonary hemorrhage: an often fatal complication of henoch-schoenlein purpura. Pediatr Dermatol. 1997;1:299–302.
doi: 10.1111/j.1525-1470.1997.tb00963.x
Ozen S, Pistorio A, Iusan SM, et al. Paediatric rheumatology international trials organisation (printo). eular/printo/pres criteria for henoch-schönlein purpura, childhood polyarteritis nodosa, childhood wegener granulomatosis and childhood takayasu arteritis: ankara 2008. part ii: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.
doi: 10.1136/ard.2009.116657
Rigante D, Castellazzi L, Bosco A, et al. Is there a crossroad between infections, genetics, and henoch-schönlein purpura? Autoimmun Rev. 2013;12(10):1016–21.
doi: 10.1016/j.autrev.2013.04.003
López-Mejías R, Genre F, Pérez BS, et al. Association of HLA-B*41:02 with henoch-schönlein purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Res Ther. 2015;17(1):102.
doi: 10.1186/s13075-015-0622-5
Trapani S, Micheli A, Grisolia F, et al. Henoch SCHONLEIN purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005;35(2):143–53.
doi: 10.1016/j.semarthrit.2005.08.007
Gómez S, Pérez M, Pellegrini M, et al. Henoch-schonlein purpura in pediatrics: ten years of experience at a moderate risk office of a general hospital. Arch Argent Pediatr. 2020;118(1):31–7.
pubmed: 31984693
Lee YH, Kim YB, Koo JW, et al. Henoch-schonlein purpura in children hospitalized at a tertiary hospital during 2004-2015 in korea: epidemiology and clinical management. Pediatr Gastroenterol Hepatol Nutr. 2016;19(3):175–85.
doi: 10.5223/pghn.2016.19.3.175
Yagnik P, Jain A, Amponsah JK, et al. National trends in the epidemiology and resource use for henoch-schönlein purpura (IgA Vasculitis) hospitalizations in the United States from 2006 to 2014. Hosp Pediatr. 2019;9(11):888–96.
doi: 10.1542/hpeds.2019-0131
Calvo-Río V, Loricera J, Mata C, et al. Henoch-schönlein purpura in northern spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore). 2014;93(2):106–13.
doi: 10.1097/MD.0000000000000019
Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. Curr Opin Rheumatol. 2013;25(2):171–8.
doi: 10.1097/BOR.0b013e32835d8e2a
Saulsbury FT. Clinical update: henoch-schönlein purpura. Lancet. 2007;369(9566):976–8.
doi: 10.1016/S0140-6736(07)60474-7
Karadağ ŞG, Tanatar A, Sönmez HE, et al. The clinical spectrum of henoch-schönlein purpura in children: a single-center study. Clin Rheumatol. 2019;38(6):1707–14.
doi: 10.1007/s10067-019-04460-1
Yamane K, Kawasaki Y, Maeda R, et al. The incidence and severity of IgA vasculitis with nephritis over a 10-year period in our hospital. Fukushima J Med Sci. 2017;63(3):135–40.
doi: 10.5387/fms.2017-14
Kounatidis D, Vadiaka M, Kouvidou C, et al. Clostridioides difficile infection in a patient with immunoglobulin A vasculitis: a triggering factor or a rare complication of the disease? A case-based review. Rheumatol Int. 2020;40(6):997–1000.
doi: 10.1007/s00296-020-04586-5
Chen JY, Mao JH. Henoch-schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015;11(11):29–34.
doi: 10.1007/s12519-014-0534-5
Chan H, Tang YL, Lv XH, et al. Risk factors associated with renal involvement in childhood henoch-schönlein purpura: a meta-analysis. PLoS One. 2016;11(11):e0167346.
doi: 10.1371/journal.pone.0167346
Nader NS, Matsumoto JM, Lteif A. Cystic changes in the ovaries of a pre-pubertal girl with henoch-schönlein purpura. J Pediatr Endocrinol Metab. 2010;23(5):517–9.
doi: 10.1515/jpem.2010.085
Modi S, Mohan M, Jennings A. Acute scrotal swelling in henoch-schonlein purpura: case report and review of the literature. Urol Case Rep. 2016;6:9–11.
doi: 10.1016/j.eucr.2016.01.004
Du L, Wang P, Liu C, et al. Multisystemic manifestations of IgA vasculitis. Clin Rheumatol. 2021;40(1):43–52.
doi: 10.1007/s10067-020-05166-5
Tracy A, Subramanian A, Adderley NJ, et al. Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data. Ann Rheum Dis. 2019;78(2):261–9.
doi: 10.1136/annrheumdis-2018-214142
Di Pietro GM, Castellazzi ML, Mastrangelo A, et al. Henoch-Schönlein purpura in children: not only kidney but also lung. Pediatr Rheumatol Online J. 2019;17(1):75.
doi: 10.1186/s12969-019-0381-y
de Graeff N, Groot N, Brogan P, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative. Rheumatology (Oxford). 2020;59(4):919.
doi: 10.1093/rheumatology/keaa057
Purevdorj N, Mu Y, Gu Y, et al. Clinical significance of the serum biomarker index detection in children with henoch-schonlein purpura. Clin Biochem. 2018;52:167–70.
doi: 10.1016/j.clinbiochem.2017.11.006
Motoyama O, Iitaka K. Henoch-Schonlein purpura with hypocomplementemia in children. Pediatr Int. 2005;47(1):39–42.
doi: 10.1111/j.1442-200x.2005.02005.x
Delbet JD, Parmentier C, Herbez Rea C, et al. Management of IgA vasculitis with nephritis. Paediatr Drugs. 2021;23(5):425–35.
doi: 10.1007/s40272-021-00464-0
Park SJ, Kim JH, Ha TS, et al. The role of corticosteroid in hemorrhagic bullous henoch schönlein purpura. Acta Paediatr. 2011;100(7):e3–4.
doi: 10.1111/j.1651-2227.2011.02219.x
Coppo R, Amore A, Peruzzi L, et al. Angiotensin antagonists and fish oil for treating IgA nephropathy. Contrib Nephrol. 2007;157:27–36.
pubmed: 17495434
Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent henoch-schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16(1):71.
doi: 10.1186/s12969-018-0285-2
Allali S, Fraitag S, Terrier B, Bodemer C, Chalumeau M. Efficacy of colchicine in a child with relapsing bullous henoch-schönlein purpura. Eur J Pediatr. 2016;175(1):147–9.
doi: 10.1007/s00431-015-2594-5
Ekinci RMK, Balci S, Melek E, et al. Clinical manifestations and outcomes of 420 children with henoch schönlein purpura from a single referral center from turkey: a three-year experience. Mod Rheumatol. 2020;30(6):1039–46.
doi: 10.1080/14397595.2019.1687074
Gupta V, Aggarwal A, Gupta R, et al. Differences between adult and pediatric onset henoch-schonlein purpura from north india. Int J Rheum Dis. 2018;21(1):292–8.
doi: 10.1111/1756-185X.13221